NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









DNAnexus

DNAnexus

Private
Mountain View, CaliforniaHealthcare & Life Scienceshttps://www.dnanexus.com/

Last Round

Series I

Mar 8, 2022

Est. Valuation

$600M

Total Funding Raised

$472.55M

Company Overview

DNAnexus is a healthcare software company that provides a secure, cloud-based platform for biomedical informatics and data management to accelerate precision health and scientific discovery.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Cloud Infrastructure, Data Integration, Drug Discovery

Business Model

B2B

Customer Profile

Usage-Based SaaS, Subscription SaaS, Services & Consulting, Government Contracts

AI Layer

Infrastructure

Keywords

bioinformatics platformprecision medicinegenomic data managementmulti-omicsbioinformatics cloudomics datahigh-performance computingHPCworkflow orchestrationclinical data integrationbio-data lakeMLOps for life sciencesdrug discovery platformgenomics cloudregulatory compliant cloudbio-tech stack

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DNAnexus Comparables

Compare DNAnexus with similar companies based on industry and business-model similarity.

DNAnexus comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Velsera
85%
Lifebit
79%
Danaher Corporation
78%

DNAnexus Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series IMar 8, 2022
Series GJun 9, 2020
Series FFeb 6, 2019
Series EJan 2, 2018
Series DApr 22, 2015
Series C
Jan 3, 2014

Key People

Founding team and executive leadership

Thomas Laur

Chief Executive Officer

Executive Team

Pieter De Leenheer

Chief Technology Officer

Executive Team

DNAnexus Investors

Notable investors and investment history

DNAnexus investors
InvestorRounds
Uncork CapitalSeed, Series B
Innovatus Capital PartnersSeries I, Series F
GVSeries E, Series I, Series G, Series C, Series F, Series B
Perceptive AdvisorsSeries I, Series G
M12 - Microsoft's Venture FundSeries E
Northpond VenturesSeries I, Series G
Foresite CapitalSeries I, Series G, Series E, Series F

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 28, 2025

    Dr. Oakland departs as VP and Product Lead for precision oncology.

  • Aug 28, 2025

    Dr. Oakland joins as VP and Product Lead.

DNAnexus Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

DNAnexus Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about DNAnexus's valuation, stock price, and market status.

Firmographic Details

HeadquartersMountain View, California
Employee Range270
Year Founded2009
Last FundingMar 8, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.